Treatment with emicizumab, a bispecific antibody and a drug that specifically targets neutrophil LFA-1, showed a positive effect in patients with haemophilia A [47] and could be a safe and effective therapeutic alternative for AAV. This evidence concerns the gene ITGB2 and hemophilia A.